Data on HCC risk with spontaneous and NA-induced HBsAg loss as reported from AASLD 2019 by Clinical Care Options (CCO)
Data from AASLD 2019 showing the benefits of regular follow-up on HCC mortality in chronic hepatitis B as reported by Clinical Care Options (CCO)
Clinical Care Options reports data from AASLD 2019 showing that adding or switching to pegIFN from stable NA therapy increases HBeAg and HBsAg loss.
HBV slides from the Clinical Care Options Symposium at the liver meeting 2019, with Paul Kwo, MD
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.